Chin Lee, M.D., M.P.H., chief medical officer at Lycia · GlobeNewswire Inc. SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc ...
Venrock Healthcare Capital Partners led the round, with participation from new investors Janus Henderson Investors, Marshall Wace and Franklin Templeton, and continued support from existing investors ...
Having spent nearly a decade at NASH-focused NGM Bio, Aetna Wun Trombley knew it would take some really compelling science to lure her away: “I was at NGM for nine years and I still love that company, ...
Eli Lilly is signing another protein degradation partner, signaling a growing commitment to the space, which seeks to tackle “undruggable” targets. The Big Pharma is handing over $35 million and ...
Lycia Therapeutics Inc. has reported progress in its immunology pipeline that comprises lysosomal targeting chimera (LYTAC)-based protein degradation therapies. The company is advancing its two lead ...
The emerging class of therapies that treat disease by using the cellular process of protein degradation focused first on cancer. But this approach also has potential applications in immunology, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results